Actemra (tocilizumab)
An approved treatment for Systemic Juvenile Idiopathic Arthritis, Giant Cell Arteritis and Systemic Sclerosis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Tocilizumab wherever you encounter it, plus the key facts at a glance.
- Generic name
- Tocilizumab
- Brand name
- Actemra
- Drug class
- Anti-IL-6 receptor antibody
- Manufacturer
- Genentech / Roche
- How it's taken
- Given as an intravenous (IV) infusion over approximately 1 hour, or as a subcutaneous injection.
The first FDA-approved drug specifically for systemic JIA.
- Tocilizumab blocks the IL-6 receptor to suppress the inflammatory cascade that drives fevers, rash, and joint destruction.
- In the TENDER trial, 85% of children responded within 12 weeks. It is also FDA approved for giant cell arteritis in adults, since May 2017, as a steroid-sparing treatment used alongside a steroid taper.
- Since March 2021 it has also been approved, as a weekly injection under the skin, to slow the loss of lung function in adults with lung disease from systemic sclerosis (SSc-ILD).
We'll email you when Actemra's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Tocilizumab fits
First FDA-approved drug specifically for systemic JIA and a cornerstone biologic option.
- IL-6 blockade is particularly effective for patients with prominent arthritis in addition to systemic features.
- Used alongside or as an alternative to IL-1 inhibitors (canakinumab, anakinra).
- Choice between IL-6 and IL-1 pathways depends on the clinical phenotype and individual response.
How Tocilizumab works
In systemic JIA, cells produce excessive amounts of IL-6, an inflammatory signaling protein that amplifies the immune attack throughout the body. IL-6 is responsible for the spiking fevers, elevated inflammatory markers, growth failure, and progressive joint damage that characterize the disease. Tocilizumab blocks the receptor where IL-6 attaches to cells, preventing the signal from being delivered.
Tocilizumab blocks both forms of the IL-6 receptor: the version attached to cell surfaces (classical signaling) and the version floating freely in the blood (trans-signaling). By blocking both, tocilizumab provides comprehensive IL-6 suppression. This leads to rapid normalization of inflammatory markers, resolution of systemic symptoms, and protection of joints from further damage.
In the TENDER trial, 85% of children with active sJIA responded within 12 weeks. By 2 years, 88% achieved JIA ACR70 responses and 40% were able to discontinue corticosteroids entirely.
Side effects and safety
Common side effects include upper respiratory infections, headache, elevated blood pressure, and infusion reactions (when given IV) such as rash, flushing, and nausea. Tocilizumab can cause liver enzyme elevations (particularly ALT/AST), especially when combined with methotrexate, requiring regular liver function monitoring. Lipid levels may increase and should be checked periodically.
Actemra carries a boxed warning for serious infections, including tuberculosis and fungal infections, that can lead to hospitalization or death; TB testing is required before starting treatment. Rare gastrointestinal perforations have been reported. Serious liver injury has occurred, in some cases leading to a liver transplant or death, and Actemra can lower neutrophil (a type of white blood cell) and platelet counts; in systemic JIA, liver tests and blood counts are checked at the second dose and then every 2 to 4 weeks.
Severe allergic reactions, including anaphylaxis that has been fatal, can happen as early as the first infusion, and serious skin reactions such as DRESS have been reported; get emergency care right away if these occur. The label also warns about a possible higher cancer risk from immune suppression, nerve disorders that damage myelin such as multiple sclerosis, and use in people with liver disease, and says live vaccines should be avoided during treatment.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Tocilizumab
Given as an intravenous (IV) infusion over approximately 1 hour, or as a subcutaneous injection. For systemic JIA, the standard IV dose is weight-based: 12mg/kg every 2 weeks for patients under 30kg, or 8mg/kg every 2 weeks for patients 30kg and above. Subcutaneous formulations are also available for some patients.
Availability and cost
Approved biosimilars: Tyenne, Tofidence, Avtozma
Help paying for Actemra
With private insurance, the drugmaker's copay card can lower what you pay for Actemra. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 4 charity funds for the conditions it treats, 1 was open on October 26, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Eligible commercially insured patients may pay as little as $0 per treatment; up to $15,000 per calendar year for drug costs.
For: private insurance · source - Free medicine program
Genentech Patient Foundation gives free ACTEMRA to eligible patients, e.g. uninsured or not covered with household income under $150,000 (more for households over 4).
For: no insurance, underinsured · source - Insurance and case manager help
Case Managers explain insurance coverage, find financial help, help with copay program enrollment and coordinate with your doctor and pharmacy.
For: private insurance, Medicare, Medicaid, no insurance · source
Good to know: Copay program excludes Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD and TRICARE. Patients under 18 need a caregiver or legal representative to manage copay help. The free-drug program is run by the separate Genentech Patient Foundation. Case Manager line: 1-800-ACTEMRA (1-800-228-3672), 6AM-5PM PT, Mon-Fri.
Charity funds
- From a charity · The Assistance FundJuvenile Arthritis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
- From a charity · The Assistance FundSystemic Sclerosis fundOpen
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and charity fund for Systemic Juvenile Idiopathic Arthritis →
Every program and charity fund for Giant Cell Arteritis →
Tocilizumab treatment timeline for Systemic Juvenile Idiopathic Arthritis
Tap how long you have been on Tocilizumab to drop your pin on the road. Your answers stay on this device.
Stage 1 of 5 · Start to 1 mo
Starting tocilizumab
Your child is starting tocilizumab (Actemra) for systemic JIA. Tocilizumab was the first drug ever specifically approved for sJIA (April 2011), so there is extensive experience with it. It blocks the IL-6 receptor, shutting down a different inflammatory pathway than IL-1 blockers like canakinumab and anakinra. The IV formulation is given every 2 weeks at an infusion center, while the subcutaneous formulation can be given at home. The 2026 ACR guidelines strongly recommend an IL-1 or IL-6 inhibitor as the first treatment for sJIA and name no preferred choice. Your child's rheumatologist can explain why tocilizumab was picked. Actemra has a boxed warning, the FDA's strongest warning, for serious infections that can lead to hospital care or death. Before starting, your child should be tested for tuberculosis, and the team watches for infection throughout treatment. Baseline labs including liver function, lipids, and blood counts have been checked.
Coming up
After the first infusion or injection, watch for improvement in fevers, rash, and joint symptoms. In the TENDER trial, 85% of children achieved significant improvement by week 12. Some children improve within the first weeks. However, there is an important monitoring consideration unique to IL-6 blockade: because IL-6 drives the fever response, tocilizumab can mask fevers from infections and even from MAS. This means your child could have a serious infection without the usual high fever warning sign. Your child's rheumatologist will monitor labs closely, checking blood counts and liver enzymes every 2-4 weeks initially. CRP will drop quickly on tocilizumab (sometimes to zero), which is expected but also means CRP can no longer be used as a reliable marker for disease flare or infection. Ferritin becomes a more important monitoring marker. Regarding vaccines: your child should not receive live vaccines while on tocilizumab. Non-live vaccines (flu shot, COVID, DTaP) can usually still be given, so ask your child's doctor about timing. Regarding home monitoring since fever is suppressed: watch for your child looking pale, unusually tired, not eating, breathing faster than normal, or just seeming off. These signs can indicate infection even when fever is absent.
Get in touch with your rheumatology team if you notice
- High ferritin with dropping blood counts, even without high fever (MAS can be masked by tocilizumab because it suppresses the fever response: ferritin and blood counts become critical markers)
- Signs of infection even without fever: looking unwell, extreme fatigue, rapid breathing, cough, or not eating (tocilizumab suppresses fever, so infections can present atypically)
- Severe abdominal pain (rare gastrointestinal perforation has been reported with tocilizumab)
- Infusion reaction: rash, difficulty breathing, or drop in blood pressure during or after IV infusion
- Significant liver enzyme elevation on first lab check
- Since tocilizumab suppresses fever, how will I know if my child has an infection?
- What is the infusion schedule, and how long does each infusion take?
- Why did you choose IL-6 blockade over IL-1 blockade for my child?
- What labs will you be monitoring, and how often?
- Can my child receive flu shots and other non-live vaccines while on tocilizumab?
- If my child is also on steroids, when can we start tapering?
Every stage of Tocilizumab treatment at a glance
Starting tocilizumab Start to 1 mo
Your child is starting tocilizumab (Actemra) for systemic JIA. Tocilizumab was the first drug ever specifically approved for sJIA (April 2011), so there is extensive experience with it. It blocks the IL-6 receptor, shutting down a different inflammatory pathway than IL-1 blockers like canakinumab and anakinra. The IV formulation is given every 2 weeks at an infusion center, while the subcutaneous formulation can be given at home. The 2026 ACR guidelines strongly recommend an IL-1 or IL-6 inhibitor as the first treatment for sJIA and name no preferred choice. Your child's rheumatologist can explain why tocilizumab was picked. Actemra has a boxed warning, the FDA's strongest warning, for serious infections that can lead to hospital care or death. Before starting, your child should be tested for tuberculosis, and the team watches for infection throughout treatment. Baseline labs including liver function, lipids, and blood counts have been checked.
After the first infusion or injection, watch for improvement in fevers, rash, and joint symptoms. In the TENDER trial, 85% of children achieved significant improvement by week 12. Some children improve within the first weeks. However, there is an important monitoring consideration unique to IL-6 blockade: because IL-6 drives the fever response, tocilizumab can mask fevers from infections and even from MAS. This means your child could have a serious infection without the usual high fever warning sign. Your child's rheumatologist will monitor labs closely, checking blood counts and liver enzymes every 2-4 weeks initially. CRP will drop quickly on tocilizumab (sometimes to zero), which is expected but also means CRP can no longer be used as a reliable marker for disease flare or infection. Ferritin becomes a more important monitoring marker. Regarding vaccines: your child should not receive live vaccines while on tocilizumab. Non-live vaccines (flu shot, COVID, DTaP) can usually still be given, so ask your child's doctor about timing. Regarding home monitoring since fever is suppressed: watch for your child looking pale, unusually tired, not eating, breathing faster than normal, or just seeming off. These signs can indicate infection even when fever is absent.
Early response 1 mo to 3 mo
Your child has had several doses of tocilizumab and the rheumatologist is evaluating the response. In the TENDER trial, by week 12, 85% achieved significant improvement and 71% reached JIA ACR70 (major improvement). If your child is responding, the systemic symptoms (fevers, rash) should have resolved and the joints should be improving. Your child's CRP is likely very low or undetectable on tocilizumab, which is the expected pharmacologic effect of blocking IL-6, not necessarily a reflection of disease quiescence. The rheumatologist is tracking the clinical picture (symptoms, joint exams, functional status) alongside labs. Steroid tapering may be underway. In the trial, 43% of children (44 of 103) were off oral steroids by week 44.
If your child is responding well, tocilizumab usually continues, with the focus on steroid tapering, growth recovery, and return to normal activities. For children with partial response (systemic features improved but significant arthritis persists): adding methotrexate is a common strategy. For children not responding by 3 months: switching from IL-6 to IL-1 blockade (canakinumab or anakinra) is the standard approach. Different children respond to different pathways, and not responding to one does not mean the other won't work. For children who initially responded but then develop worsening: reassess for MAS (which can be subtle on tocilizumab), infection, or true treatment failure.
Response assessment 3 mo to 6 mo
By 3-6 months, your child's response pattern is clear. In the TENDER trial, 80% of children receiving tocilizumab at week 52 had at least 70% improvement with no fever. That 80% included 59% with 90% improvement. By week 52, 52% had stopped oral steroids. Your rheumatologist is evaluating whether inactive disease has been achieved. The goals are the same as with any sJIA biologic: no fevers, no rash, no active arthritis, normal lab markers, and importantly, normal growth velocity. Many children have been able to lower or stop steroids by this point. Your rheumatologist may be ordering screening for sJIA-associated lung disease, as the 2026 ACR guidelines conditionally recommend routine screening.
For children doing well, tocilizumab continues with regular lab checks. The Actemra label advises blood counts and liver tests at the second dose and then every 2 to 4 weeks in sJIA. The 2026 ACR guidelines suggest these tests within the first 1 to 2 months, then every 3 to 4 months. Ask your rheumatologist which schedule fits your child. Lipid levels should be checked periodically (tocilizumab can raise cholesterol). Growth should be tracked carefully. For children with persistent arthritis despite good systemic control: combination with methotrexate may help. For children with inadequate overall response: switching biologics or discussing clinical trials is appropriate. If your child has been off steroids and in inactive disease for several months, the long-term plan will focus on maintaining this and eventually discussing whether to attempt biologic tapering.
Maintenance treatment 6 mo to 2 yr
Your child is in the maintenance phase. If inactive disease has been achieved, the infusion or injection schedule continues as the ongoing routine. Lab checks continue on the schedule your rheumatologist sets. The label advises every 2 to 4 weeks in sJIA. The treatment priorities during this phase are maintaining disease control, supporting normal growth and development, managing any side effects (especially monitoring lipids and liver enzymes), keeping up with non-live vaccinations, and ensuring your child can participate fully in school, sports, and social activities.
Once inactive disease has lasted a while, your rheumatologist may discuss tapering tocilizumab. The 2026 ACR guidelines did not agree on how long to wait first. Some doctors space out doses or lower them before stopping, although the label notes dose reduction has not been studied in sJIA. Some children successfully come off biologics and remain in remission. Others flare when treatment is reduced and need to stay on long-term therapy. If a flare happens, the 2026 ACR guidelines suggest going back to the plan that last worked. Your rheumatologist will also begin discussing transition planning to adult care if your child is approaching adolescence.
Long-term management 2 yr on
Your child has been on tocilizumab for 2 years or more. The long-term outlook for sJIA has improved substantially with targeted biologic therapy. Your child may still be on scheduled infusions, may have tapered to a reduced schedule, or may have successfully discontinued. Comprehensive care at this stage includes disease monitoring, growth and development tracking, psychosocial support, and preparation for the eventual transition to adult rheumatology care.
Long-term management focuses on sustained remission, quality of life, and transition planning. If your child is approaching the teenage years, introducing the concept of gradually taking ownership of their own healthcare is important. This includes understanding their condition, knowing their medications, and eventually communicating directly with their doctor. Your child's rheumatologist will continue periodic monitoring and reassessment of whether ongoing biologic therapy is necessary.
This timeline shows typical patterns from the prescribing information, guidelines and published studies. Your own treatment may differ, and your rheumatology team is the source of truth for your plan. Last checked against the FDA label on .
Sources
Clinical trial results
The Phase 3 TENDER trial was the pivotal study for sJIA approval. At week 12, 85.3% of tocilizumab-treated patients achieved JIA ACR30 with absence of fever, compared to 24.3% on placebo. JIA ACR70 was reached by 70% versus 8% on placebo. By week 104 (2 years), 88% achieved ACR70 and 71% reached ACR90. Corticosteroid reduction was significant: 40% of patients discontinued steroids entirely by week 44.
Development history
Tocilizumab was originally developed through a collaboration between Osaka University and Chugai Pharmaceutical. Roche/Genentech brought it to global markets. After success in rheumatoid arthritis (approved 2010), the TENDER trial in systemic JIA demonstrated remarkable efficacy. FDA approved tocilizumab for sJIA in April 2011, making it the first drug specifically approved for this condition.
It also has indications for rheumatoid arthritis, giant cell arteritis, polyarticular JIA, systemic sclerosis-associated ILD, cytokine release syndrome, and COVID-19 in certain hospitalized adults and children 2 years and older.
Explore Systemic Juvenile Idiopathic Arthritis and Giant Cell Arteritis and Systemic Sclerosis trials
Other Systemic Juvenile Idiopathic Arthritis & Giant Cell Arteritis treatments
Common questions about Tocilizumab
▸What is Tocilizumab (Actemra)?
The first FDA-approved drug specifically for systemic JIA. Tocilizumab blocks the IL-6 receptor to suppress the inflammatory cascade that drives fevers, rash, and joint destruction. In the TENDER trial, 85% of children responded within 12 weeks. It is also FDA approved for giant cell arteritis in adults, since May 2017, as a steroid-sparing treatment used alongside a steroid taper. Since March 2021 it has also been approved, as a weekly injection under the skin, to slow the loss of lung function in adults with lung disease from systemic sclerosis (SSc-ILD).
▸How does Tocilizumab work?
In systemic JIA, cells produce excessive amounts of IL-6, an inflammatory signaling protein that amplifies the immune attack throughout the body. IL-6 is responsible for the spiking fevers, elevated inflammatory markers, growth failure, and progressive joint damage that characterize the disease. Tocilizumab blocks the receptor where IL-6 attaches to cells, preventing the signal from being delivered.
Tocilizumab blocks both forms of the IL-6 receptor: the version attached to cell surfaces (classical signaling) and the version floating freely in the blood (trans-signaling). By blocking both, tocilizumab provides comprehensive IL-6 suppression. This leads to rapid normalization of inflammatory markers, resolution of systemic symptoms, and protection of joints from further damage.
In the TENDER trial, 85% of children with active sJIA responded within 12 weeks. By 2 years, 88% achieved JIA ACR70 responses and 40% were able to discontinue corticosteroids entirely.
▸What are the side effects of Tocilizumab?
Common side effects include upper respiratory infections, headache, elevated blood pressure, and infusion reactions (when given IV) such as rash, flushing, and nausea. Tocilizumab can cause liver enzyme elevations (particularly ALT/AST), especially when combined with methotrexate, requiring regular liver function monitoring. Lipid levels may increase and should be checked periodically. Actemra carries a boxed warning for serious infections, including tuberculosis and fungal infections, that can lead to hospitalization or death; TB testing is required before starting treatment. Rare gastrointestinal perforations have been reported. Serious liver injury has occurred, in some cases leading to a liver transplant or death, and Actemra can lower neutrophil (a type of white blood cell) and platelet counts; in systemic JIA, liver tests and blood counts are checked at the second dose and then every 2 to 4 weeks. Severe allergic reactions, including anaphylaxis that has been fatal, can happen as early as the first infusion, and serious skin reactions such as DRESS have been reported; get emergency care right away if these occur. The label also warns about a possible higher cancer risk from immune suppression, nerve disorders that damage myelin such as multiple sclerosis, and use in people with liver disease, and says live vaccines should be avoided during treatment.
▸How is Tocilizumab taken?
Given as an intravenous (IV) infusion over approximately 1 hour, or as a subcutaneous injection. For systemic JIA, the standard IV dose is weight-based: 12mg/kg every 2 weeks for patients under 30kg, or 8mg/kg every 2 weeks for patients 30kg and above. Subcutaneous formulations are also available for some patients.
▸Is Tocilizumab FDA approved?
Yes, Tocilizumab (Actemra) is FDA approved (2010) for the treatment of Systemic Juvenile Idiopathic Arthritis and Giant Cell Arteritis and Systemic Sclerosis.
▸Is Actemra approved for systemic JIA?
Yes. Actemra (tocilizumab) was the first FDA-approved drug specifically for systemic JIA, approved in April 2011. It blocks the IL-6 receptor to control fevers, inflammation, and joint damage. [2]
▸What is the difference between tocilizumab and canakinumab for sJIA?
Tocilizumab blocks the IL-6 receptor, while canakinumab blocks IL-1 beta. Both are first-line biologic options for systemic JIA. IL-6 blockade with tocilizumab may be preferred when arthritis is prominent, while IL-1 blockade is often favored when systemic features like fevers dominate. [2]
▸What are the side effects of Actemra?
Common side effects of Actemra (tocilizumab) include upper respiratory infections, headache, elevated blood pressure, and infusion reactions such as rash, flushing, and nausea when given by IV. Actemra carries a boxed warning for serious infections, including tuberculosis and fungal infections, so TB testing is required before starting, and it can raise liver enzymes and lipid levels and lower neutrophil and platelet counts, which are checked with regular blood tests. Severe allergic reactions, including anaphylaxis, can happen as early as the first infusion, and live vaccines should be avoided during treatment. [2]
▸What did the TENDER trial show for tocilizumab?
In the Phase 3 TENDER trial, 85.3% of children treated with tocilizumab achieved a JIA ACR30 response with no fever at week 12, compared with 24.3% on placebo, and 70% reached JIA ACR70 versus 8% on placebo. By week 104, 88% achieved ACR70 and 71% reached ACR90. Steroid reduction was significant, with 40% of patients discontinuing corticosteroids entirely by week 44. [1][3]
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- New England Journal of Medicine · 2012. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. https://www.nejm.org/doi/full/10.1056/NEJMoa1112802
- U.S. Food and Drug Administration. ACTEMRA (tocilizumab) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125276s148lbl.pdf
- Genentech / Roche. Actemra for Systemic JIA, Clinical Trial Results. https://www.actemra.com/sjia/proven-results/clinical-trial.html